Lara Sullivan - Oct 7, 2021 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Executive Officer, Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
Stock symbol
PYXS
Transactions as of
Oct 7, 2021
Transactions value $
$0
Form type
4
Date filed
10/12/2021, 07:47 PM
Next filing
Apr 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to buy) Award $0 +962K $0.00 962K Oct 7, 2021 Common Stock 962K $16.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Two-thirds of these stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, and one-third of these stock options vest in full on the fourth anniversary of the October 7, 2021 grant date, all subject to the reporting person's continued employment through the applicable vesting date.